# US Whole Exome Sequencing Market

> United States Whole Exome Sequencing Market Research Report By Product (kits, systems, services) By End-User (research centers and government institutes, hospitals and diagnostics centers, pharmaceuticals & biotechnology companies) By Technology (sequencing by synthesis (SBS), ION semiconductor sequencing) By Application (diagnostics, drug discovery and development, agriculture and animal research) - Growth & Industry Forecast 2025 To 2035

- **Forecast Period:** 2025 - 2035
- **CAGR:** 20.2%
- **2024:** $ 346.18 Million
- **2025:** $ 416.11 Million
- **2035:** $ 2,620.2 Million
- **Key Players:** Illumina (US), Thermo Fisher Scientific (US), Agilent Technologies (US), BGI Genomics (CN), Roche (CH), QIAGEN (DE), PerkinElmer (US), F. Hoffmann-La Roche (CH)

**Report ID:** MRFR/HC/18548-HCR · **Pages:** 100 · **Author:** Vikita Thakur & Garvit Vyas · **Last Updated:** May 13, 2026

**URL:** https://www.marketresearchfuture.com/reports/us-whole-exome-sequencing-market-20095

---

## Market Summary

## US Whole Exome Sequencing Market Highlighted Trends & Dynamics

The US Whole Exome Sequencing (WES) Market is growing due to genomic medicine advances. WES sequences the genome's protein-coding regions to reveal a person's genetics. The richness of genetic information helps diagnose genetic abnormalities, forecast disease risk, and personalize medical treatments.

Growing genetic abnormalities boost WES market demand. WES helps discover uncommon and inherited illnesses for early intervention and better treatment as awareness develops and more people get genetic testing.

WES is vital in precision medicine, where therapies are based on a patient's genetic profile. WES is being used to discover genetic abnormalities that may affect treatment results due to the desire for individualized diagnoses and focused therapeutics. This affects oncology and uncommon illness treatment.

WES is used more for cancer genetics in oncology. Exome analysis reveals cancer-causing genetic alterations. This information helps doctors choose targeted medicines, estimate treatment responses, and create tailored cancer treatment regimens, fueling WES market demand.

WES incorporation into clinical research is driving market growth. WES data is helping researchers and drug firms find genetic markers, biomarkers, and therapeutic targets. Genomic and clinical research cooperation increases therapy development and healthcare innovation.

WES is becoming more used in pediatric genetic testing to diagnose genetic abnormalities early. The extensive exome coverage enables for the identification of genetic variations responsible for pediatric disorders, allowing prompt treatments, informed family planning, and better healthcare outcomes for children and their families.

WES demand is driven by sequencing technology advances. WES is increasingly used in clinical and research contexts because to advances in sequencing speed, accuracy, and cost.

WES is in demand due to its strong diagnostic yield and clinical value. Clinicians seeking accurate diagnoses, especially in situations where standard diagnostic approaches are ambiguous, may use WES to discover causal genetic variations in a broad variety of illnesses.

WES demand is rising as patients learn about genetic testing's advantages. WES is sought by patients, particularly those with a family history of genetic illnesses, to understand their genetic predispositions, make educated healthcare choices, and manage their health.

The WES sector faces data interpretation and genetic counseling hurdles despite rising demand. Genetic counseling helps people and families comprehend genetic discoveries since genomic data is complicated and needs professional interpretation. Maximizing WES' therapeutic effect requires addressing these difficulties.

## Market Drivers

### 0

{"key"=>"0", "value"=>"
 
 
{\"key\"=>\"Increased Focus on Rare Diseases\", \"value\"=>\"
The rising focus on rare diseases is influencing the whole exome-sequencing market. With approximately 7,000 known rare diseases affecting millions in the US, there is a growing need for effective diagnostic tools. Whole exome sequencing offers a comprehensive approach to identifying genetic mutations responsible for these conditions. In 2025, it is estimated that around 80% of rare diseases have a genetic component, highlighting the relevance of this technology. As healthcare systems prioritize the diagnosis and treatment of rare diseases, the whole exome-sequencing market is likely to see substantial growth, driven by both patient demand and clinical necessity.
\"}
"}

### 1

{"key"=>"1", "value"=>"
 
 
{\"key\"=>\"Rising Demand for Genetic Testing\", \"value\"=>\"
The increasing awareness of genetic disorders and the importance of early diagnosis is driving the whole exome-sequencing market. Patients and healthcare providers are recognizing the value of genetic testing in personalized medicine. According to recent data, the market for genetic testing in the US is projected to reach approximately $10 billion by 2026, with whole exome sequencing playing a pivotal role. This demand is fueled by the need for tailored treatment plans and the ability to identify hereditary conditions. As more individuals seek genetic insights, the whole exome-sequencing market is likely to expand, providing healthcare professionals with essential tools for effective patient management.
\"}
"}

### 2

{"key"=>"2", "value"=>"
 
 
{\"key\"=>\"Advancements in Bioinformatics Solutions\", \"value\"=>\"
Advancements in bioinformatics solutions are playing a crucial role in the whole exome-sequencing market. The ability to analyze and interpret vast amounts of genomic data is essential for the effective application of whole exome sequencing. In 2025, the bioinformatics market is projected to reach $5 billion, with a significant portion dedicated to genomic data analysis. Enhanced software tools and algorithms are enabling researchers and clinicians to derive meaningful insights from sequencing data, thereby improving diagnostic accuracy. As bioinformatics continues to evolve, it is expected to bolster the whole exome-sequencing market by facilitating more efficient data processing and interpretation.
\"}
"}

### 3

{"key"=>"3", "value"=>"
 
 
{\"key\"=>\"Growing Investment in Genomic Technologies\", \"value\"=>\"
Investment in genomic technologies is a key driver of the whole exome-sequencing market. Venture capital funding for biotech companies specializing in genomic sequencing has surged, with estimates suggesting an increase of over 30% in 2025 compared to previous years. This influx of capital is enabling companies to innovate and enhance their sequencing platforms, making them more accessible and cost-effective. As the technology becomes more affordable, healthcare providers are likely to adopt whole exome sequencing more widely, further propelling market growth. The trend indicates a robust future for the whole exome-sequencing market as it aligns with the broader shift towards precision medicine.
\"}
"}

### 4

{"key"=>"4", "value"=>"
 
 
{\"key\"=>\"Integration of Exome Sequencing in Research\", \"value\"=>\"
The integration of whole exome sequencing into research initiatives is significantly impacting the whole exome-sequencing market. Academic institutions and research organizations are increasingly utilizing this technology to explore genetic variations associated with diseases. This trend is supported by funding from government agencies, which has seen a rise in grants for genomic research. In 2025, the National Institutes of Health (NIH) allocated over $3 billion for genomic research, indicating a strong commitment to advancing this field. As research continues to uncover the genetic basis of diseases, the whole exome-sequencing market is expected to benefit from increased collaboration between academia and industry.
\"}
"}

## Future Outlook

The [Whole Exome Sequencing Market](https://www.marketresearchfuture.com/reports/whole-exome-sequencing-market-8763) is projected to grow at a 20.2% CAGR from 2025 to 2035, driven by advancements in genomics, increasing demand for personalized medicine, and technological innovations.

**New opportunities:**

- Development of integrated bioinformatics platforms for data analysis. Expansion of direct-to-consumer exome sequencing services. Partnerships with healthcare providers for personalized treatment plans.

By 2035, the market is expected to achieve substantial growth, driven by innovation and strategic partnerships.

## Segment Insights

### By Product: Kits (Largest) vs. Services (Fastest-Growing)

In the US whole exome-sequencing market, the distribution of market share among products such as kits, systems, and services reveals that kits hold the largest share. Kits are favored for their comprehensive solutions, appealing to various labs and research institutions seeking efficient and reliable sequencing methods. Conversely, services, while currently smaller in market share, are gaining traction as facilities and institutions increasingly outsource sequencing needs to specialized providers that offer expertise and high-throughput capacities. The growth trends within the product segment are significantly influenced by technological advancements and the rising demand for personalized medicine. As healthcare evolves, the need for fast and accurate genetic testing is driving the adoption of exome sequencing services. Additionally, as research institutions focus on cutting-edge capabilities, the trend toward utilizing external services rather than in-house systems is expected to persist, cementing services as the fastest-growing product category in this market.

Kits: Dominant vs. Services: Emerging

Kits, as the dominant product in the US whole exome-sequencing market, provide comprehensive solutions that integrate sample preparation and sequencing processes. They are characterized by their ease of use and efficiency, making them the preferred choice for many laboratories conducting varied genomic studies. On the other hand, services represent an emerging segment, growing rapidly as institutions increasingly seek specialized expertise and high-throughput capabilities for genome sequencing. Services not only offer flexibility and scalability but also allow labs to focus on other critical tasks, thus aligning with trends toward collaboration and resource optimization in genetic research.

### By Technology: Sequencing by Synthesis (Largest) vs. ION Semiconductor Sequencing (Fastest-Growing)

In the US whole exome-sequencing market, the technology segment showcases a clear dominance of the sequencing by synthesis (SBS) method, which captures a significant share due to its established reliability and accuracy. Conversely, ION semiconductor sequencing is rapidly gaining traction, appealing to a growing number of laboratories and institutions due to its innovative approach and cost-effectiveness. This dynamic results in a competitive landscape marked by evolving technological capabilities and shifting consumer preferences. The growth trajectory in this segment is largely driven by advancements in sequencing technologies and increasing investments in genomics research. The shift towards personalized medicine is leading to greater adoption of exome sequencing, with ION semiconductor sequencing emerging as an attractive alternative for rapid and efficient genomic analysis. This momentum not only enhances accessibility to whole exome sequencing but also facilitates its integration into clinical practice, paving the way for future innovations.

Technology: Sequencing by Synthesis (Dominant) vs. ION Semiconductor Sequencing (Emerging)

Sequencing by synthesis (SBS) remains the dominant technology in the US whole exome-sequencing market, renowned for its robustness, precision, and ability to generate high-quality data. Its widespread acceptance is bolstered by a vast array of applications across research and clinical settings, solidifying its position in the market. On the other hand, ION semiconductor sequencing, though emerging, is making significant strides due to its rapid processing capabilities and reduced costs. This technology utilizes a novel approach that simplifies the sequencing process, appealing to laboratories focusing on efficiency and scalability. Together, these technologies contribute to a rich ecosystem in exome sequencing, catering to diverse needs and continuously pushing the boundaries of genomic research.

### By Application: Diagnostics (Largest) vs. Drug Discovery and Development (Fastest-Growing)

In the US whole exome-sequencing market, the diagnostics segment holds the largest share, driven by the increasing prevalence of genetic disorders and the rising demand for personalized medicine. Drug discovery and development follows, gaining traction due to its innovation-driven nature and the requirement for advanced analytical techniques. Agriculture and animal research, while significant, represents a smaller portion of the application landscape, primarily serving niche markets. Currently, drug discovery and development is noted as the fastest-growing segment, fueled by investments in biotechnology and pharmaceutical research. This growth is propelled by advancements in sequencing technologies which facilitate the identification of genetic factors in diseases. The diagnostics field continues to expand as healthcare entities adopt genomic data to improve patient outcomes, fostering a competitive landscape among service providers.

Diagnostics: Dominant vs. Drug Discovery and Development: Emerging

The diagnostics segment is characterized by its extensive application in clinical settings, providing vital information for disease identification and management. Its dominance stems from the established infrastructure for genetic testing and the mounting focus on preventive healthcare measures. In contrast, drug discovery and development, while emerging, showcases a dynamic potential driven by innovative research and collaborations between academic institutions and the pharmaceutical industry. This segment is distinguished by its cutting-edge methodologies and the increasing integration of exome sequencing in clinical trials, aligning with the objectives of precision medicine and tailored therapeutic solutions.

### By End-User: Hospitals and Diagnostics Centers (Largest) vs. Pharmaceuticals & Biotechnology Companies (Fastest-Growing)

In the US whole exome-sequencing market, the distribution of market share among the three primary end-user segments is led by hospitals and diagnostics centers, which account for a substantial portion of the overall market. Following behind are research centers and government institutes, which play a critical role although they hold a smaller share compared to the healthcare facilities. Meanwhile, the pharmaceutical and biotechnology companies are significantly increasing their market presence through innovative programs and research initiatives. The growth trends within this segment are notable, particularly for pharmaceuticals and biotechnology companies, which are rapidly adopting whole exome sequencing to enhance drug development and personalized medicine. The increased emphasis on genetic testing and research capabilities is driving investments in these areas, allowing companies to leverage exome sequencing in clinical trials, thus connecting therapeutic advancements with genetic insights for improved patient outcomes.

Hospitals and Diagnostics Centers (Dominant) vs. Pharmaceuticals & Biotechnology Companies (Emerging)

Hospitals and diagnostics centers dominate the US whole exome-sequencing market due to their high demand for advanced genomic solutions in clinical settings. This segment benefits from established infrastructures and the capability to conduct a vast number of tests regularly. They are essential in ensuring accurate diagnoses, thus contributing to the overall health management of patients. On the other hand, pharmaceuticals and biotechnology companies are emerging as key players, leveraging whole exome sequencing for drug development and research. Their investment in genomic studies aligns with the growing trend toward personalized medicine, propelling their growth and adoption of exome sequencing technologies to optimize therapeutic outcomes and support innovative treatments.

## Competitive Benchmarking

The [whole exome-sequencing market](https://www.marketresearchfuture.com/reports/whole-exome-sequencing-market-8763) is characterized by a dynamic competitive landscape, driven by advancements in genomic technologies and increasing demand for personalized medicine. Key players such as Illumina (US), Thermo Fisher Scientific (US), and Agilent Technologies (US) are at the forefront, each adopting distinct strategies to enhance their market positioning. Illumina (US) focuses on innovation through continuous development of next-generation sequencing technologies, while Thermo Fisher Scientific (US) emphasizes strategic partnerships to expand its product offerings. Agilent Technologies (US) is leveraging its expertise in bioinformatics to provide integrated solutions, thereby enhancing its competitive edge. Collectively, these strategies contribute to a robust competitive environment, fostering innovation and collaboration across the sector. In terms of business tactics, companies are increasingly localizing manufacturing and optimizing supply chains to enhance operational efficiency. The market appears moderately fragmented, with several key players exerting significant influence. This structure allows for a diverse range of offerings, catering to various customer needs while fostering healthy competition among established and emerging firms. In October 2025, Illumina (US) announced a collaboration with a leading healthcare provider to integrate its sequencing technology into routine clinical practice. This strategic move is likely to enhance patient access to genomic testing, thereby positioning Illumina (US) as a leader in the clinical application of whole exome sequencing. The partnership underscores the growing trend of integrating genomic data into healthcare, which may significantly impact patient outcomes and treatment personalization. In September 2025, Thermo Fisher Scientific (US) launched a new exome sequencing platform designed to streamline workflows and reduce turnaround times. This innovation is expected to bolster the company’s market share by addressing the increasing demand for rapid and accurate genomic analysis. The introduction of this platform reflects a broader industry trend towards efficiency and speed in genomic testing, which is crucial for meeting the needs of healthcare providers and researchers alike. In August 2025, Agilent Technologies (US) expanded its bioinformatics capabilities through the acquisition of a software company specializing in genomic data analysis. This acquisition is anticipated to enhance Agilent's product portfolio, allowing for more comprehensive solutions in whole exome sequencing. By integrating advanced bioinformatics tools, Agilent (US) aims to provide customers with deeper insights into genomic data, thereby strengthening its competitive position in the market. As of November 2025, current competitive trends indicate a strong emphasis on digitalization, sustainability, and the integration of artificial intelligence (AI) in genomic research and applications. Strategic alliances are increasingly shaping the landscape, enabling companies to pool resources and expertise to drive innovation. Looking ahead, competitive differentiation is likely to evolve from traditional price-based competition towards a focus on technological advancements, innovative solutions, and reliable supply chains. This shift may redefine market dynamics, emphasizing the importance of quality and innovation in meeting the growing demands of the healthcare sector.

## Report Scope

| MARKET SIZE 2024 | 346.18(USD Million) |
| --- | --- |
| MARKET SIZE 2025 | 416.11(USD Million) |
| MARKET SIZE 2035 | 2620.2(USD Million) |
| COMPOUND ANNUAL GROWTH RATE (CAGR) | 20.2% (2025 - 2035) |
| REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
| BASE YEAR | 2024 |
| Market Forecast Period | 2025 - 2035 |
| Historical Data | 2019 - 2024 |
| Market Forecast Units | USD Million |
| Key Companies Profiled | Illumina (US), Thermo Fisher Scientific (US), Agilent Technologies (US), BGI Genomics (CN), Roche (CH), QIAGEN (DE), PerkinElmer (US), F. Hoffmann-La Roche (CH) |
| Segments Covered | Product, Technology, Application, End-User |
| Key Market Opportunities | Advancements in personalized medicine drive demand for whole exome-sequencing market innovations and applications. |
| Key Market Dynamics | Technological advancements drive competitive dynamics in the whole exome-sequencing market, enhancing diagnostic capabilities and research applications. |
| Countries Covered | US |

## Frequently Asked Questions

**Q: What was the market valuation of the US whole exome-sequencing market in 2024?**
A: The market valuation was $346.18 Million in 2024.

**Q: What is the projected market valuation for the US whole exome-sequencing market by 2035?**
A: The projected valuation for 2035 is $2620.2 Million.

**Q: What is the expected CAGR for the US whole exome-sequencing market during the forecast period 2025 - 2035?**
A: The expected CAGR during this period is 20.2%.

**Q: Which companies are considered key players in the US whole exome-sequencing market?**
A: Key players include Illumina, Thermo Fisher Scientific, Agilent Technologies, BGI Genomics, Roche, QIAGEN, PerkinElmer, and F. Hoffmann-La Roche.

**Q: What are the main product segments in the US whole exome-sequencing market?**
A: Main product segments include kits, systems, and services, with services valued at $196.18 Million in 2024.

**Q: How does the technology segment of the US whole exome-sequencing market perform?**
A: The technology segment includes sequencing by synthesis (SBS) valued at $276.18 Million in 2024.

**Q: What applications drive the US whole exome-sequencing market?**
A: Key applications include diagnostics and drug discovery, each valued at $138.47 Million in 2024.

**Q: Which end-users are prominent in the US whole exome-sequencing market?**
A: Prominent end-users include hospitals and diagnostics centers, valued at $138.48 Million in 2024.

**Q: What is the projected growth trend for the US whole exome-sequencing market?**
A: The market is expected to grow significantly, reaching $2620.2 Million by 2035.

**Q: What was the valuation of the sequencing by synthesis technology in 2024?**
A: The sequencing by synthesis technology was valued at $276.18 Million in 2024.


---

*This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/us-whole-exome-sequencing-market-20095*